Home » Authors » Kim Coghill

Articles by Kim Coghill

ImClone, BMS File New BLA Seeking Approval Of Erbitux

Aug. 15, 2003

Minus the Waksal brothers, ImClone Systems Inc. and Bristol-Myers Squibb Co. forged ahead and, as planned, filed a biologics license application for the investigational IgG1 monoclonal antibody Erbitux for metastatic colorectal cancer. (BioWorld Today)

ImClone, BMS File New BLA Seeking Approval Of Erbitux

Aug. 15, 2003

Minus the Waksal brothers, ImClone Systems Inc. and Bristol-Myers Squibb Co. forged ahead and, as planned, filed a biologics license application for the investigational IgG1 monoclonal antibody Erbitux for metastatic colorectal cancer. (BioWorld Today)

NIH Grant Of $35M Fueling Extensive Study Of Lipids

Aug. 14, 2003

NIH Grant Of $35M Fueling Extensive Study Of Lipids

Aug. 14, 2003

FDA Rule That Limits Patent Stacking Set To Go Into Effect

Aug. 13, 2003

FDA Rule That Limits Patent Stacking Set To Go Into Effect

Aug. 13, 2003

ViroPharma Licenses CMV Drug From Glaxo For $3.5M Up Front

Aug. 12, 2003

ViroPharma Licenses CMV Drug From Glaxo For $3.5M Up Front

Aug. 12, 2003

Pfizer Joins Effort To Limit Sales Of Drugs From Canada

Aug. 11, 2003

Pfizer Joins Effort To Limit Sales Of Drugs From Canada

Aug. 11, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...